Non-responders, and the honest state of the evidence about them
The mechanism is well described. The variance is not.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Everything filed in December 2024, the month of Volume 1, Number 12. The issue itself — cover, editor’s letter and table of contents — is here.
The mechanism is well described. The variance is not.
The evidence base is thin and the document says so, which is to its credit.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Reported from the analysis, not from a warning notice.
A peptide has a monoisotopic mass and an average mass, they differ by several daltons at this molecular size, and a certificate that does not say which it quotes cannot be…
The mechanism is well described. The variance is not.
The document is four pages. Three of them are about dates.
Follow the resin, not the catalogue.
Reported from the analysis, not from a warning notice.
The observation that closes a facility is rarely the dramatic one.
We give background rates alongside trial rates, because an event occurring during treatment is not thereby caused by it.
A withdrawal trial answers a narrower question than it appears to. This piece states which question.
Efficacy was never the question in this appraisal. Duration of treatment was.
Follow the resin, not the catalogue.
Reported from the analysis, not from a warning notice.
Reported from the sessions, and from the two hours afterwards.
The Journal has read several hundred certificates from twenty companies. We set out what the documents actually cover, and what a reader is filling in from imagination.
The older-adult diet-and-exercise trials are the closest analogue to rapid pharmacological weight loss, and they are twenty years old.
A proper account of an operation that existed, and of what closing it cost.
The evidence base is thin and the document says so, which is to its credit.
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The limit for a parenteral product is calculable from the dose and the body weight in two lines. Almost nobody in this trade performs the calculation.
Endotoxin is the more tractable of the two questions, and a kinetic chromogenic determination is neither slow nor exotic. It is simply not on the menu.
Almost every practical recommendation in circulation was established in a population that does not resemble the people now following it.
The observation that closes a facility is rarely the dramatic one.
The evidence base is thin and the document says so, which is to its credit.
Follow the resin, not the catalogue.
Efficacy was never the question in this appraisal. Duration of treatment was.
Concentrations fall by half a week, so a month away leaves a small fraction of steady state. Resuming at the previous dose presents the receptor with a step it has not seen…
The document is four pages. Three of them are about dates.
A proper account of an operation that existed, and of what closing it cost.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Efficacy was never the question in this appraisal. Duration of treatment was.
Every instrument specification quoted in an advertisement is a best case obtained on a calibration mixture, not on a submitted vial.
The most consequential features of most certificates in this market are the tests that do not appear on them at all.
The observation that closes a facility is rarely the dramatic one.
A reminder that a purity figure is the output of a method, and that methods differ.
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Real-world persistence figures, with their definitions stated, because the definitions are doing most of the work.
What a verification mark would have to carry to be checkable: a date, a lot, a method, a submitter and a link to the report.